Table 4.

Lenalidomide maintenance after autologous HSCT

Lenalidomide maintenance after autologous HSCT

EFS indicates event-free survival (includes deaths, progressions, and second cancers); IT, intensive therapy; NIT, nonintensive therapy; and ND, no difference.

Adapted from McCarthy et al.42 

Close Modal

or Create an Account

Close Modal
Close Modal